Venous Ulcer Market to Witness Significant Growth by 2032 | DelveInsight

The Venous Ulcer market across the 7MM is expected to experience significant growth due to the development of novel therapies, rising awareness, and changing demographic trends. Key companies, including Reponex Pharmaceuticals, Energenesis Biomedical, MediWound, Solascure Limited, TR Therapeutics, Promore Pharma AB, NovaLead Pharma, RHEACELL, Merakris Therapeutics, MTF Biologics, and others, are leveraging advanced technologies to address unmet clinical needs in this market.
DelveInsight's report titled "Venous Leg Ulcer - Market Insight, Epidemiology And Market Forecast - 2032 [https://www.delveinsight.com/report-store/venous-leg-ulcer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" offers comprehensive epidemiological data along with insights into market trends, an analysis of the competitive landscape, current and emerging therapeutic approaches, and assessments of the patient journey regarding venous leg ulcers.

The report forecasts that the venous leg ulcer market across the 7MM, which includes the United States, the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan, will grow at a considerable CAGR by 2032. This anticipated growth is attributed to increasing prevalence, development of novel therapies (such as stem cell therapy, growth factor therapy, and hyperbaric oxygen therapy), rising awareness, and demographic changes such as higher obesity rates, hypertension, diabetes, and sedentary lifestyles.

Download the Venous Ulcer Market report to understand which factors are driving the venous ulcer therapeutic market @ Venous Ulcer Market Trends [https://www.delveinsight.com/sample-request/venous-leg-ulcer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

The report reveals that the US has the highest prevalence of venous leg ulcers among the 7MM, primarily due to lifestyle factors such as obesity and physical inactivity. VLUs represent 60-80% of all leg ulcers, with an overall prevalence between 0.18% and 1%, increasing to 4% in individuals over 65. In Europe, age-adjusted rates are elevated due to an aging population. Notably, 33-60% of VLUs become chronic, persisting for more than six weeks. These trends are projected to drive market growth during the forecast period (2025-2032).

Discover evolving trends in the venous ulcer patient pool forecasts @ Venous Ulcer Epidemiology Analysis [https://www.delveinsight.com/sample-request/venous-leg-ulcer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

The report also examines current venous ulcer treatment practices, emerging drugs, market shares of individual therapies, and unmet medical needs. Standard treatment methods for venous ulcers typically include compression therapy, leg elevation, wound care, and infection prevention. However, despite these interventions, venous ulcers often persist for months or even years, posing significant challenges for both patients and healthcare providers.

Most current treatments, such as, Micronized purified flavonoid fraction (MPFF), pentoxifylline, sulodexide (SDX), and mesoglycan focus on passive management rather than actively stimulating the healing process, underscoring the critical need for innovative therapeutic approaches that can accelerate wound closure and improve long-term outcomes for individuals suffering from these chronic wounds.

Merakris Therapeutics has emerged as a leader in addressing this unmet need with their biological drug, Dermacyte Liquid, also referred to as MTX-001. According to interim Phase II trial results published in March 2025, this injectable cell-free amniotic fluid has demonstrated remarkable efficacy in treating chronic, non-healing venous leg ulcers. Notably, the therapy achieved complete wound closure within one month for patients who had ulcers persisting for a median of 7 months despite prior standard interventions.

Another promising advancement comes from MTF Biologics with their AmnioBand Membrane, an aseptically processed, dehydrated human amnion/chorion allograft. A recent study demonstrated that AmnioBand achieved full wound closure in 75% of patients with chronic venous leg ulcers after just 12 weeks of treatment, making it one of the most cost-effective advanced treatment options available today.

Discover recent advancements in the venous ulcer treatment landscape @ Venous Ulcer Recent Developments [https://www.delveinsight.com/sample-request/venous-leg-ulcer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

As these innovative therapies, among others, progress through clinical development, the venous skin ulcer treatment landscape is poised for significant transformation. The integration of biological, surgical, and technological approaches provides renewed hope for patients, addressing unmet needs in the field and driving market growth.

Table of Contents

1. Key Insights

2. Executive Summary of Venous Leg Ulcer

3. Competitive Intelligence Analysis for Venous Leg Ulcer

4. Venous Leg Ulcer: Market Overview at a Glance

5. Venous Leg Ulcer: Disease Background and Overview

6. Patient Journey

7. Venous Leg Ulcer Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Venous Leg Ulcer Unmet Needs

10. Key Endpoints of Venous Leg Ulcer Treatment

11. Venous Leg Ulcer Marketed Products

12. Venous Leg Ulcer Emerging Therapies

13. Venous Leg Ulcer: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Venous Leg Ulcer

17. KOL Views

18. Venous Leg Ulcer Market Drivers

19. Venous Leg Ulcer Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Related Reports

Venous Leg Ulcers Pipeline Insight [https://www.delveinsight.com/sample-request/venous-leg-ulcers-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

The Venous Leg Ulcers Pipeline Insight Report provides comprehensive insights about the venous leg ulcers pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the venous leg ulcers companies, including Reponex Pharmaceuticals, Energenesis Biomedical, MediWound, Solascure limited, TR Therapeutics, Promore Pharma AB, NovaLead Pharma, and RHEACELL, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=venous-ulcer-market-to-witness-significant-growth-by-2032-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.